SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kambiz Rahbar discussing the clinical value of the PROSTest to detect biochemical recurrence in ...

SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kambiz Rahbar discussing the utility of the PROSTest to predict response to 177 Lu-PSMA therapy in ...

(UroToday.com) The 2025 SNMMI annual meeting featured a prostate cancer and dosimetry session and a presentation by Dr. Loic Djaileb discussing clinical protocols to monitor efficacy of 177 Lu-PSMA ...

ASCO 2025 phase 1b/2 study assessing 9MW2821, nectin-4 antibody drug conjugate, toripalimab in treatment-naïve patients, locally advanced or metastatic urothelial carcinoma.

ASCO 2025 results of AREN1721, phase 2 trial of axitinib + nivolumab combination therapy, nivolumab, TFE/translocation RCC, COG-led NCTN phase 2 trial of nivolumab + axitinib.

ASCO 2025, Renal Cancer, kidney cancer, Non-clear cell renal cell carcinoma (non-ccRCC), Ipilimumab, nivolumab, SUNNIFORECAST Trial, Tumor Nephrectomy, tyrosine kinase inhibitors (TKIs), immune ...

ASCO 2025, bladder cancer, muscle-invasive bladder cancer (MIBC), trimodal therapy (TMT), SWOG 8710 trial, PURE-01 trial, NIAGARA trial, ABACUS trial, CheckMate 274 trial, ImVigor 010, atezolizumab, ...

ASCO 2025 post-hoc analysis of TheraP, clonal hematopoiesis, metastatic castration-resistant prostate cancer (mCRPC), 177Lu-PSMA-617, cabazitaxel, PSMA-targeted radioligand.

ASCO 2025 CA209-8TY trial, phase 2 trial of nivolumab and ipilimumab, stereotactic body radiation therapy, metastatic castration-resistant prostate cancer (mCRPC), androgen receptor pathway inhibitors ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a prostate, testicular, and penile cancers ...

ASCO 2025, urothelial carcinoma (UC), Metastatic Bladder Cancer, Enfortumab Vedotin (EV), Dose Reduction in Metastatic Bladder Cancer, Nectin-4.

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, was host to the Session State of the Art Lecture: Personalizing treatment for patients with ...